Chromosome 18 Loss of Heterozygosity in Small Intestinal Neuroendocrine Tumours: Multi-Omic and Tumour Composition Analyses.
Cell composition
DNA methylation
Multi-omics
Small intestinal neuroendocrine tumours
Journal
Neuroendocrinology
ISSN: 1423-0194
Titre abrégé: Neuroendocrinology
Pays: Switzerland
ID NLM: 0035665
Informations de publication
Date de publication:
2023
2023
Historique:
received:
20
12
2022
accepted:
06
03
2023
medline:
31
8
2023
pubmed:
13
3
2023
entrez:
12
3
2023
Statut:
ppublish
Résumé
Small intestinal neuroendocrine tumours (siNETs) are rare neoplasms which present with low mutational burden and can be subtyped based on copy number variation (CNV). Currently, siNETs can be molecularly classified as having chromosome 18 loss of heterozygosity (18LOH), multiple CNVs (MultiCNV), or no CNVs. 18LOH tumours have better progression-free survival when compared to MultiCNV and NoCNV tumours, however, the mechanism underlying this is unknown, and clinical practice does not currently consider CNV status. Here, we use genome-wide tumour DNA methylation (n = 54) and gene expression (n = 20 matched to DNA methylation) to better understand how gene regulation varies by 18LOH status. We then use multiple cell deconvolution methods to analyse how cell composition varies between 18LOH status and determine potential associations with progression-free survival. We identified 27,464 differentially methylated CpG sites and 12 differentially expressed genes between 18LOH and non-18LOH (MultiCNV + NoCNV) siNETs. Although few differentially expressed genes were identified, these genes were highly enriched with the differentially methylated CpG sites compared to the rest of the genome. We identified differences in tumour microenvironment between 18LOH and non-18LOH tumours, including CD14+ infiltration in a subset of non-18LOH tumours which had the poorest clinical outcomes. We identify a small number of genes which appear to be linked to the 18LOH status of siNETs, and find evidence of potential epigenetic dysregulation of these genes. We also find a potential prognostic marker for worse progression-free outcomes in the form of higher CD14 infiltration in non-18LOH siNETs.
Identifiants
pubmed: 36907174
pii: 000530106
doi: 10.1159/000530106
pmc: PMC10614519
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
915-923Subventions
Organisme : Cancer Research UK
ID : A29019
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/5
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C18281/A30905
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C18281/A29019
Pays : United Kingdom
Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Mol Cancer Ther. 2013 Sep;12(9):1848-59
pubmed: 23804703
Epigenetics Chromatin. 2015 Jan 27;8:6
pubmed: 25972926
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Bioinformatics. 2020 Dec 11;:
pubmed: 33313760
Nat Genet. 2003 Jan;33(1):61-5
pubmed: 12496760
Nat Commun. 2018 Aug 13;9(1):3220
pubmed: 30104673
Hepatogastroenterology. 2011 Mar-Apr;58(106):352-8
pubmed: 21661395
Oncol Rep. 2013 Dec;30(6):2725-32
pubmed: 24064911
Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4
pubmed: 18077471
Mol Cancer Ther. 2009 Dec;8(12):3331-40
pubmed: 19996273
J Clin Invest. 2015 Sep;125(9):3335-7
pubmed: 26325031
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Math Biosci Eng. 2021 Oct 18;18(6):8951-8961
pubmed: 34814330
Bioinformatics. 2013 Jan 15;29(2):189-96
pubmed: 23175756
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1428-35
pubmed: 25586243
Bioinformatics. 2019 Dec 15;35(24):5298-5300
pubmed: 31297508
Oncol Lett. 2017 Mar;13(3):1281-1287
pubmed: 28454247
Virchows Arch. 2019 Jan;474(1):3-12
pubmed: 30368555
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Cell. 2010 May 14;141(4):559-63
pubmed: 20478246
Clin Epigenetics. 2019 Nov 27;11(1):166
pubmed: 31775891
Nature. 2013 Oct 24;502(7472):472-9
pubmed: 24153300
Oncotarget. 2018 Feb 12;9(19):14922-14938
pubmed: 29599916
Clin Cancer Res. 2016 Jan 1;22(1):250-8
pubmed: 26169971
Biomed Pharmacother. 2019 Mar;111:1243-1248
pubmed: 30841438
Cancers (Basel). 2021 Aug 26;13(17):
pubmed: 34503115
Bioinformatics. 2014 Feb 01;30(3):428-30
pubmed: 24336642
Genome Biol. 2020 Sep 4;21(1):221
pubmed: 32883324
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4725-30
pubmed: 25825750
BMC Bioinformatics. 2017 Jan 18;18(1):41
pubmed: 28100166
Endocr Relat Cancer. 2019 Jan 1;26(1):119-130
pubmed: 30400003
Bioinformatics. 2016 Jan 15;32(2):286-8
pubmed: 26424855
Nat Rev Genet. 2012 May 29;13(7):484-92
pubmed: 22641018
Genome Biol. 2013;14(10):R115
pubmed: 24138928
Front Immunol. 2018 Jul 30;9:1697
pubmed: 30105018